{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:23:50Z","timestamp":1786685030871,"version":"build-2736575974"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0099","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:01Z","timestamp":1752836041000},"source":"Crossref","is-referenced-by-count":5,"title":["The early detection, diagnostic evaluation, and local treatment of prostate cancer: A paradigm shift"],"prefix":"10.3238","author":[{"given":"Peter","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Franiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"10.3238\/arztebl.m2025.0099_ref1","unstructured":"RKI: Krebs in Deutschland. In: Krebsregisterdaten Zf (eds.): Robert Koch Institut 2022."},{"key":"10.3238\/arztebl.m2025.0099_ref2","doi-asserted-by":"crossref","unstructured":"Worst TS, Surovtsova I, Vogel T, et al.: [Incidence, therapy, and prognosis of prostate cancer in Baden-W\u00fcrttemberg: Analysis based on cancer registry data]. Urologie 2024; 63: 681\u201392","DOI":"10.1007\/s00120-024-02275-w"},{"key":"10.3238\/arztebl.m2025.0099_ref3","doi-asserted-by":"crossref","unstructured":"James ND, Tannock I, N\u2018Dow J, et al.: The Lancet Commission on prostate cancer: Planning for the surge in cases. Lancet 2024; 403: 1683\u2013722","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"10.3238\/arztebl.m2025.0099_ref4","doi-asserted-by":"crossref","unstructured":"de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ; ERSPC Rotterdam Study Group: A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol 2023; 85: 426\u201334","DOI":"10.1016\/j.eururo.2023.03.016"},{"key":"10.3238\/arztebl.m2025.0099_ref5","doi-asserted-by":"crossref","unstructured":"Arsov C, Albers P, Herkommer K, et al.: A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial. Int J Cancer 2022; 150: 1861\u20139","DOI":"10.1002\/ijc.33940"},{"key":"10.3238\/arztebl.m2025.0099_ref6","doi-asserted-by":"crossref","unstructured":"Bratt O, Godtman RA, Jiborn T, et al.: Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. Eur Urol 2024; 85: 207\u201314","DOI":"10.1016\/j.eururo.2023.11.013"},{"key":"10.3238\/arztebl.m2025.0099_ref7","doi-asserted-by":"crossref","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J, et al.: Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med 2022; 387: 2126\u201337","DOI":"10.1056\/NEJMoa2209454"},{"key":"10.3238\/arztebl.m2025.0099_ref8","doi-asserted-by":"crossref","unstructured":"Fazekas T, Shim SR, Basile G, et al.: Magnetic resonance imaging in prostate cancer screening: A systematic review and meta-analysis. JAMA Oncol 2024; 10: 745\u201354","DOI":"10.1001\/jamaoncol.2024.0734"},{"key":"10.3238\/arztebl.m2025.0099_ref9","doi-asserted-by":"crossref","unstructured":"Vickers AJ, Ulmert D, Sjoberg DD, et al.: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40\u201355 and long term risk of metastasis: case-control study. BMJ 2013; 346: f2023","DOI":"10.1136\/bmj.f2023"},{"key":"10.3238\/arztebl.m2025.0099_ref10","unstructured":"Tillmanns H: Fr\u00fcherkennung: Die Teilnahmeraten sind oft noch zu niedrig. WIDO\u2014Wissenschaftliches Institut der AOK 2020."},{"key":"10.3238\/arztebl.m2025.0099_ref11","unstructured":"Krilaviciute A, Lakes J, Radtke JP, et al.: Digital rectal examination (DRE) is not useful as a solitary screening tool for prostate cancer in young men\u2014results from the PROBASE trial. Eur Urol Oncol 2023; 6; 566-73"},{"key":"10.3238\/arztebl.m2025.0099_ref12","doi-asserted-by":"crossref","unstructured":"Krilaviciute A, Kaaks R, Seibold P, et al.: Risk-adapted Screening for Prostate Cancer \u2013 Re-defining the Low-Risk Group by data from the PROBASE trial. Eur Urol 2024; 86: 493\u2013500","DOI":"10.1016\/j.eururo.2024.04.030"},{"key":"10.3238\/arztebl.m2025.0099_ref13","doi-asserted-by":"crossref","unstructured":"Drost FH, Osses DF, Nieboer D, et al.: Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; 4: Cd012663","DOI":"10.1002\/14651858.CD012663.pub2"},{"key":"10.3238\/arztebl.m2025.0099_ref14","doi-asserted-by":"crossref","unstructured":"Franiel T, Asbach P, Beyersdorff D, et al.: mpMRI of the Prostate (MR-Prostatography): Updated recommendations of the DRG and BDR on patient preparation and scanning protocol. RoFo 2021; 193: 763\u201377","DOI":"10.1055\/a-1406-8477"},{"key":"10.3238\/arztebl.m2025.0099_ref15","doi-asserted-by":"crossref","unstructured":"Schoots IG, Padhani AR: Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int 2021; 127: 175\u20138","DOI":"10.1111\/bju.15277"},{"key":"10.3238\/arztebl.m2025.0099_ref16","doi-asserted-by":"crossref","unstructured":"Quentin M, Boschheidgen M, Radtke JP, et al.: MRI in-bore biopsy following MRI\/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer. Eur J Radiol 2024; 175: 111436","DOI":"10.1016\/j.ejrad.2024.111436"},{"key":"10.3238\/arztebl.m2025.0099_ref17","doi-asserted-by":"crossref","unstructured":"Pagniez MA, Kasivisvanathan V, Puech P, Drumez E, Villers A, Olivier J: Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: A systematic review and meta-analysis. J Urol 2020; 204: 24\u201332","DOI":"10.1097\/JU.0000000000000757"},{"key":"10.3238\/arztebl.m2025.0099_ref18","doi-asserted-by":"crossref","unstructured":"Alberts AR, Roobol MJ, Verbeek JFM, et al.: Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol 2019; 75: 310\u20138","DOI":"10.1016\/j.eururo.2018.07.031"},{"key":"10.3238\/arztebl.m2025.0099_ref19","doi-asserted-by":"crossref","unstructured":"Hu JC, Assel M, Allaf ME, et al.: Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: The PREVENT Randomized Trial. Eur Urol 2024; 86: 61\u20138","DOI":"10.1016\/j.eururo.2023.12.015"},{"key":"10.3238\/arztebl.m2025.0099_ref20","doi-asserted-by":"crossref","unstructured":"Mian BM, Feustel PJ, Aziz A, et al.: Complications following transrectal and transperineal prostate biopsy: Results of the ProBE-PC randomized clinical trial. J Urol 2024; 211: 205\u201313","DOI":"10.1097\/JU.0000000000003788"},{"key":"10.3238\/arztebl.m2025.0099_ref21","doi-asserted-by":"crossref","unstructured":"Ploussard G, Barret E, Fiard G, et al.: Transperineal versus transrectal magnetic resonance imaging-targeted biopsies for prostate cancer diagnosis: Final results of the randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol 2024; 7: 1080\u20137","DOI":"10.1016\/j.euo.2024.01.019"},{"key":"10.3238\/arztebl.m2025.0099_ref22","doi-asserted-by":"crossref","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al.: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet 2020; 395: 1208\u201316","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"10.3238\/arztebl.m2025.0099_ref23","doi-asserted-by":"crossref","unstructured":"Pritchard CC, Mateo J, Walsh MF, et al.: Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016; 375: 443\u201353","DOI":"10.1056\/NEJMc1611137"},{"key":"10.3238\/arztebl.m2025.0099_ref24","doi-asserted-by":"crossref","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al.: Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547\u201358","DOI":"10.1016\/j.eururo.2023.08.014"},{"key":"10.3238\/arztebl.m2025.0099_ref25","doi-asserted-by":"crossref","unstructured":"Sauter G, Steurer S, Clauditz TS, et al.: Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 2016; 69: 592\u20138","DOI":"10.1016\/j.eururo.2015.10.029"},{"key":"10.3238\/arztebl.m2025.0099_ref26","doi-asserted-by":"crossref","unstructured":"Stolzenburg JU, Holze S, Neuhaus P, et al.: Robotic-assisted versus laparoscopic surgery: Outcomes from the first multicentre, randomised, patient-blinded controlled trial in radical prostatectomy (LAP-01). Eur Urol 2021; 79: 750\u20139","DOI":"10.1016\/j.eururo.2021.01.030"},{"key":"10.3238\/arztebl.m2025.0099_ref27","doi-asserted-by":"crossref","unstructured":"Haney CM, Kowalewski KF, Westhoff N, et al.: Robot-assisted versus conventional laparoscopic radical prostatectomy: A systematic review and meta-analysis of randomised controlled trials. Eur Urol Focus 2023; 9: 930\u20137","DOI":"10.1016\/j.euf.2023.05.007"},{"key":"10.3238\/arztebl.m2025.0099_ref28","doi-asserted-by":"crossref","unstructured":"Tilki D, Chen MH, Wu J, et al.: Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death. J Clin Oncol 2021; 39: 2284\u201393","DOI":"10.1200\/JCO.20.03714"},{"key":"10.3238\/arztebl.m2025.0099_ref29","doi-asserted-by":"crossref","unstructured":"Parker CC, Petersen PM, Cook AD, et al.: Timing of radiotherapy (RT) after radical prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol 2024; 35: 656\u201366","DOI":"10.1016\/j.annonc.2024.05.001"},{"key":"10.3238\/arztebl.m2025.0099_ref30","doi-asserted-by":"crossref","unstructured":"Van den Broeck T, van den Bergh RCN, Briers E, et al.: Biochemical recurrence in prostate cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus 2020; 6: 231\u20134","DOI":"10.1016\/j.euf.2019.06.004"},{"key":"10.3238\/arztebl.m2025.0099_ref31","doi-asserted-by":"crossref","unstructured":"Bottke D, Miksch J, Thamm R, et al.: Changes of radiation treatment concept based on (68)Ga-PSMA-11-PET\/CT in early PSA-recurrences after radical prostatectomy. Front Oncol 2021; 11: 665304","DOI":"10.3389\/fonc.2021.665304"},{"key":"10.3238\/arztebl.m2025.0099_ref32","doi-asserted-by":"crossref","unstructured":"Lee WR, Dignam JJ, Amin MB, et al.: Long-term analysis of NRG oncology RTOG 0415: A randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2024; 42: 2377\u201381","DOI":"10.1200\/JCO.23.02445"},{"key":"10.3238\/arztebl.m2025.0099_ref33","doi-asserted-by":"crossref","unstructured":"Niazi T, Nabid A, Malagon T, et al.: Hypofractionated dose escalation radiotherapy for high-risk prostate cancer: The survival analysis of the prostate cancer study 5, a groupe de radio-oncologie g\u00e9nito-urinaire du Quebec-led phase 3 trial. Int J Radiat Oncol Biol Phys. 2024; 118: 52\u201362","DOI":"10.1016\/j.ijrobp.2023.05.014"},{"key":"10.3238\/arztebl.m2025.0099_ref34","doi-asserted-by":"crossref","unstructured":"Corrao G, Marvaso G, Mastroleo F, et al.: Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis. Radiother Oncol 2024; 195: 110264","DOI":"10.1016\/j.radonc.2024.110264"},{"key":"10.3238\/arztebl.m2025.0099_ref35","doi-asserted-by":"crossref","unstructured":"van As N, Griffin C, Tree A, et al.: Phase 3 trial of stereotactic body radiotherapy in localized Prostate Cancer. N Engl J Med 2024; 391: 1413\u201325","DOI":"10.1056\/NEJMoa2403365"},{"key":"10.3238\/arztebl.m2025.0099_ref36","doi-asserted-by":"crossref","unstructured":"Groen VH, Haustermans K, Pos FJ, et al.: Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer. Eur Urol 2022; 82: 252\u20137","DOI":"10.1016\/j.eururo.2021.12.012"},{"key":"10.3238\/arztebl.m2025.0099_ref37","doi-asserted-by":"crossref","unstructured":"Murthy V, Maitre P, Kannan S, et al.: Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial. Clin Oncol 2021; 39: 1234\u201342","DOI":"10.1200\/JCO.20.03282"},{"key":"10.3238\/arztebl.m2025.0099_ref38","doi-asserted-by":"crossref","unstructured":"Attard G, Murphy L, Clarke NW, et al.: Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399: 447\u201360","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"10.3238\/arztebl.m2025.0099_ref39","doi-asserted-by":"crossref","unstructured":"Michalski JM, Winter KA, Prestidge BR, et al.: Effect of brachytherapy with external beam radiation therapy versus brachytherapy alone for intermediate-risk prostate cancer: NRG oncology RTOG 0232 randomized clinical trial. J Clin Oncol 2023; 41: 4035\u201344","DOI":"10.1200\/JCO.22.01856"},{"key":"10.3238\/arztebl.m2025.0099_ref40","doi-asserted-by":"crossref","unstructured":"Luining WI, Hagens MJ, Meijer D, et al.: The probability of metastases within different prostate-specific antigen ranges using prostate-specific membrane antigen positron emission tomography in patients with newly diagnosed prostate cancer. Eur Urol Open Sci 2024; 59: 55\u201362","DOI":"10.1016\/j.euros.2023.12.001"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:41Z","timestamp":1752836081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0099","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}